Welcome to the #MEDSHED! Needing a brief, concise review of clinical pharmacotherapy and disease management? Direct links of reference to content discussed? Look no further than the #MEDSHED series based on infographics and carousel presentations!
๐ PK/PD: Inotropes - #MEDSHED
๐ Inotropes are pharmacologic agents that increase cardiac output and contractility in the setting of acute heart failure with hypoperfusion.
๐ Commonly used inotropes include dobutamine, milrinone, and isoproterenol.
๐ Dobutamine
Mechanism
B1, B2, A1 agonist
B2 agonism (peripheral vasodilation) counteracts A1 activity (vasoconstriction)
Starting Rate: 2 - 5 mcg/kg/min
Titrate to clinical response
Max Rate: 20 mcg/kg/min
Metabolism
Renal - inactive metabolites
Precautions/Considerations
Ventricular arrhythmias
Reduced efficacy in patients on chronic beta blocker therapy
๐ Milrinone
Mechanism
Phosphodiesterase inhibitor --> cAMP mediated increase ionized Ca2+ and contractile force of cardiac muscle
Starting Rate: 0.125 - 0.25 mcg/kg/min
Titrate to clinical response
Dose Range: 0.125 - 0.75 mcg/kg/minute
Metabolism
Hepatic --> excreted as unchanged drug via urine (may accumulate with renal failure)
Precautions/Considerations
Ventricular arrhythmias
Dose reduction with renal insufficiency
Hypotension
๐ Isoproterenol
Mechanism
Potent B1, B2 agonist
Dose-dependent hypotension secondary to unopposed B2 agonism
Starting Rate: 1 mcg/min
Titrate to clinical response
Dose Range: 1 - 20 mcg/min
Metabolism
Hepatic via catechol O-methyltransferase
Precautions/Considerations
Ventricular arrhythmias
Hypotension
Reduced efficacy in patients on chronic beta blocker therapy
๐ Website: www.pharmwyze.com
Shop: www.pharmwyze.com/shop
Donate $5: www.pharmwyze.com//_paylink/AY78_L7r
Social Links: links.pharmwyze.com
Streaming Platforms: https://pharmwyze.hopp.to/podstreams
Patreon: www.patreon.com/pharmwyze
Paypal Donation: https://pharmwyze.hopp.to/paypaldonate
PHARMWYZE SITREP Newsletter: https://www.pharmwyze.com/sitrepnewsletter
Not medical advice. Educational purposes only. No relationships to report.
Comments